Physicians' Academy for Cardiovascular Education

Atrial fibrillation

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Nov. 12, 2023 - Jeff Healey, MD

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 4, 2023 - Amy Groenewegen, MD

Unexpected results after switching from VKA to DOAC in frail older patients with AF

3' education - Aug. 28, 2023 - Linda Joosten, MD

Lessons from a trial with colchicine in patients undergoing thoracic surgery

3' education - Aug. 27, 2023 - Lukas Hoes, MD and David Conen, MD

Colchicine fails to reduce perioperative AF or MI in patients undergoing major thoracic surgery

3' education - Aug. 26, 2023 - David Conen, MD

No signal for efficacy of DOAC in patients with atrial high-rate episodes

3' education - Aug. 25, 2023 - Paulus Kirchhof, MD

The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

10' education - May 26, 2023 - Lale Tokgözoğlu, MD

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

Screening using a smartphone-app more than doubles detection rate of AF

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD

Atrial fibrillation: From risk prediction to clinical outcomes

10' education - Apr. 6, 2022 - Prof. Stefan Hohnloser, MD

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD

Screening for AF with irregular heart rhythm detection by Fitbit wearables

3' education - Nov. 14, 2021 - Steven Lubitz, MD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

Initiating digoxin in AF patients associated with early hazard of sudden death

3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Tailoring oral anticoagulation in elderly patients with AF

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

Outstanding questions and ongoing studies on the use of NOACs

3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Phase 3 study with FXIa inhibitor stopped early due to inferior efficacy

News - Nov. 21, 2023

The OCEANIC-AF study will be stopped early due to a lack of efficacy. The study investigates the effects of FXIa inhibitor asundexian compared to apixaban on the risk of stroke and systemic embolism in patients with AF at risk of stroke.

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Nov. 12, 2023 - Jeff Healey, MD
**AHA 2023** In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

AHA 2023 In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

DOAC reduces stroke in patients with subclinical atrial fibrillation

News - Nov. 12, 2023

AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.

Factor XI inhibitor reduces major or clinically relevant non-major bleeding in AF patients

News - Nov. 12, 2023

AHA 2023 What are the findings of a phase 2 trial in which two doses of the FXI/XIa inhibitor abelacimab were compared with rivaroxaban with regard to the safety outcome of bleeding in patients with AF?

Effects of SGLT2 inhibitor not modified by the coexistence of AF in patients with HFpEF

Literature - Oct. 24, 2023 - Filippatos G, et al. - Eur J Heart Fail. 2023

In a secondary analysis of the EMPEROR-Preserved trial, the beneficial effects of empagliflozin on cardiovascular and renal outcomes were consistent in patients with HFpEF regardless of AF.

Increased risk of CV death, HF and AF in breast cancer survivors

Literature - Oct. 5, 2023 - Galimzhanov A, et al. - Eur J Prev Cardiol. 2023

A meta-analysis showed that breast cancer survivors have an increased risk of CV death, HF, and AF, but not of CAD, MI, or ischemic stroke, compared with the general population.

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 4, 2023 - Amy Groenewegen, MD
**ESC Congress 2023** In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

Phase 2 study with FXI inhibitor in AF stopped early due to overwhelming efficacy

News - Sep. 19, 2023

The AZALEA-TIMI 71 trial, in which the efficacy of the factor XI/XIa inhibitor abelacimab was compared with rivaroxaban in patients with AF at moderate-to-high risk of stroke, has been stopped early due to an overwhelming reduction in bleeding.

Consistent treatment effect of DOAC regardless of valvular heart disease etiology and event risk

News - Sep. 5, 2023

ESC Congress 2023 An analysis of the RIVER trial showed that among patients with atrial fibrillation or flutter and a bioprosthetic mitral valve, patients with rheumatic heart disease did not have an increased risk of thrombotic and bleeding events.

Improvement of early diagnosis of CVD in primary care patients with COPD or T2D

News - Sep. 4, 2023

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.

Unexpected results after switching from VKA to DOAC in frail older patients with AF

3' education - Aug. 28, 2023 - Linda Joosten, MD
**ESC Congress 2023** In the FRAIL-AF trial, frail older adults with AF were randomized to switch from a VKA to a DOAC or to continue using a VKA. Linda Joosten talks about the unexpected results of this trial.

ESC Congress 2023 In the FRAIL-AF trial, frail older adults with AF were randomized to switch from a VKA to a DOAC or to continue using a VKA. Linda Joosten talks about the unexpected results of this trial.

Switching to DOAC associated with higher risk of bleeding in frail patients with AF

News - Aug. 28, 2023

ESC Congress 2023 The FRAIL-AF trial showed that frail older patients with AF who switched from VKA to a DOAC had a 69% higher risk of bleeding, compared with patients who continued using VKA. There was no difference between DOACs and VKA in stroke reduction in this patient population.